[go: up one dir, main page]

CO2018008558A2 - Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes - Google Patents

Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes

Info

Publication number
CO2018008558A2
CO2018008558A2 CONC2018/0008558A CO2018008558A CO2018008558A2 CO 2018008558 A2 CO2018008558 A2 CO 2018008558A2 CO 2018008558 A CO2018008558 A CO 2018008558A CO 2018008558 A2 CO2018008558 A2 CO 2018008558A2
Authority
CO
Colombia
Prior art keywords
cells
molecules
treatment
autoimmune diseases
protein
Prior art date
Application number
CONC2018/0008558A
Other languages
English (en)
Inventor
Jeffrey Greve
Original Assignee
Delinia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delinia Inc filed Critical Delinia Inc
Publication of CO2018008558A2 publication Critical patent/CO2018008558A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)

Abstract

Proteína de fusión que comprende una proteína agonista selectiva de IL2αβγ (agonista selectivo de IL2) y una proteína IgG Fc unidas a través de un conector. La unidad agonista selectiva de IL2 presenta actividad terapéutica al activar selectivamente la forma del receptor IL2αβγ, con lo que puede estimular selectivamente las células T reguladoras. La unidad Fc provee una vida media en la circulación más prolongada que la de una proteína IL-2 o IL2SA.
CONC2018/0008558A 2016-01-20 2018-08-15 Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes CO2018008558A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/002,144 US20170204154A1 (en) 2016-01-20 2016-01-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
PCT/US2017/014090 WO2017127514A1 (en) 2016-01-20 2017-01-19 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
CO2018008558A2 true CO2018008558A2 (es) 2018-08-21

Family

ID=59314394

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0008558A CO2018008558A2 (es) 2016-01-20 2018-08-15 Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes

Country Status (16)

Country Link
US (7) US20170204154A1 (es)
EP (1) EP3405482A4 (es)
JP (2) JP6983787B2 (es)
KR (1) KR20180100237A (es)
CN (1) CN108602871A (es)
AU (2) AU2017210187B2 (es)
BR (1) BR112018014671A2 (es)
CA (1) CA3010621A1 (es)
CL (1) CL2018001951A1 (es)
CO (1) CO2018008558A2 (es)
EA (1) EA201891656A1 (es)
EC (1) ECSP18062614A (es)
MX (1) MX2018008840A (es)
SG (1) SG11201805784PA (es)
WO (1) WO2017127514A1 (es)
ZA (1) ZA201804458B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697688B2 (en) 2018-03-13 2023-07-11 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3172227T (lt) * 2014-07-21 2020-02-10 Delinia, Inc. Molekulės, kurios selektyviai aktyvina reguliacines t ląsteles, skirtos autoimuninių ligų gydymui
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20190083656A (ko) 2016-11-08 2019-07-12 데리니아, 인크. 자가면역 질환의 치료를 위한 il-2 변이체
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN113166220A (zh) * 2018-03-09 2021-07-23 奥美药业有限公司 创新细胞因子前药
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
EP3827079A1 (en) * 2018-07-25 2021-06-02 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3108865A1 (en) 2018-08-06 2020-02-13 Medikine, Inc. Il-2 receptor binding compounds
CN113286812A (zh) 2018-09-27 2021-08-20 西里欧发展公司 掩蔽型细胞因子多肽
AU2019369498A1 (en) * 2018-10-31 2021-05-20 Delinia, Inc. Multivalent regulatory T cell modulators
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
WO2021021606A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
CN114514241A (zh) * 2019-08-15 2022-05-17 赛缇姆治疗公司 经修饰的白细胞介素2(il-2)多肽、缀合物以及其用途
WO2021052277A1 (zh) * 2019-09-16 2021-03-25 上海泽生科技开发股份有限公司 重组人神经调节蛋白衍生物及其用途
CA3160133A1 (en) 2019-11-05 2021-05-14 Medikine, Inc. Il-2rbyc binding compounds
JP7427287B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之ｉｌ２促效劑及其使用方法（二）
CN115315436A (zh) 2020-01-10 2022-11-08 明峰治疗股份公司 修饰的il-2多肽及其用途
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
IL295303A (en) 2020-02-03 2022-10-01 Medikine Inc 7-il alpha receptor binding compounds and preparations containing them
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
TWI815194B (zh) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2023548311A (ja) 2020-10-29 2023-11-16 ブリストル－マイヤーズ スクイブ カンパニー 疾患の治療のための融合タンパク質
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
CN113789346A (zh) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 长效化重组人白细胞介素2融合蛋白及其制备方法和应用
JP2025506173A (ja) * 2022-02-11 2025-03-07 ビステラ， インコーポレイテッド 自己免疫疾患の治療のためのインターロイキン－２ムテイン
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2024054868A1 (en) * 2022-09-07 2024-03-14 Xencor, Inc. An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic dermatitis
WO2024178000A2 (en) * 2023-02-21 2024-08-29 Sorrento Therapeutics, Inc. Polynucleotides encoding modified interleukin 2 (il2) polypeptides, and methods of making and using the same

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
JPH03500415A (ja) 1988-07-05 1991-01-31 アムジエン・インコーポレーテツド インターロイキン２類似体
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU5134693A (en) 1993-09-21 1995-04-10 Amgen, Inc. Method for treating psoriasis
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
FI104522B (fi) 1998-04-28 2000-02-15 Abb Control Oy Kytkinvarokerunko
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
IL154925A0 (en) 2000-09-14 2003-10-31 Beth Israel Hospital Modulation of il-2 and il-15-mediated t cell responses
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
NZ530545A (en) 2001-07-11 2006-10-27 Maxygen Holdings Ltd Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
AU2002319696B2 (en) 2001-07-27 2007-11-01 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Systems for in vivo site-directed mutagenesis using oligonucleotides
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
RU2312677C9 (ru) * 2001-12-04 2008-03-27 Мерк Патент Гмбх Иммуноцитокины с модулированной селективностью
US7452968B2 (en) 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
PT1641823E (pt) 2003-06-12 2011-11-08 Lilly Co Eli Proteínas de fusão de análogos de glp-1
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
EP1944318B1 (en) 2003-07-21 2011-03-02 Transgene S.A. Multifunctional cytokines
US7267960B2 (en) * 2003-07-25 2007-09-11 Amgen Inc. Antagonists and agonists of LDCAM and methods of use
CA2557677A1 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
RU2404795C2 (ru) 2005-01-27 2010-11-27 Новартис Вэксинс Энд Диагностикс Инк. Способы лечения почечно-клеточной карциномы
EP1688146B1 (en) 2005-02-07 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Preparing aldesleukin for pharmaceutical use
EP3357932A1 (en) 2006-09-29 2018-08-08 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
FR2918770B1 (fr) 2007-07-10 2009-09-11 Essilor Int Afficheur destine a etre integre a une paire de lunettes.
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
ES2825173T3 (es) 2009-01-21 2021-05-14 Amgen Inc Composiciones y métodos de tratamiento de enfermedades inflamatorias y autoinmunitarias
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
EP2443137B1 (en) 2009-06-15 2015-05-20 Biokine Therapeutics Ltd. Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
MX388465B (es) 2010-11-12 2025-03-20 Nektar Therapeutics Conjugados de un resto de interleucina-2 y un polímero.
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
CN102174111B (zh) 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
DK3489255T3 (da) 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
ES2811624T3 (es) 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN103193887B (zh) 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
LT3172227T (lt) * 2014-07-21 2020-02-10 Delinia, Inc. Molekulės, kurios selektyviai aktyvina reguliacines t ląsteles, skirtos autoimuninių ligų gydymui
PL3180020T3 (pl) 2014-08-11 2019-06-28 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6941561B2 (ja) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR102687530B1 (ko) 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
KR20190083656A (ko) 2016-11-08 2019-07-12 데리니아, 인크. 자가면역 질환의 치료를 위한 il-2 변이체

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US11697688B2 (en) 2018-03-13 2023-07-11 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11787866B2 (en) 2018-03-13 2023-10-17 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US11802160B2 (en) 2018-03-13 2023-10-31 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US11802161B2 (en) 2018-03-13 2023-10-31 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11814434B2 (en) 2018-03-13 2023-11-14 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11851494B2 (en) 2018-03-13 2023-12-26 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11873341B2 (en) 2018-03-13 2024-01-16 Tusk Therapeutics Ltd. Anti-CD25 for tumour specific cell depletion
US11919960B2 (en) 2018-03-13 2024-03-05 Tusk Therapeutics Ltd. Anti-CD25 antibody agents

Also Published As

Publication number Publication date
US20190202882A1 (en) 2019-07-04
US10766938B2 (en) 2020-09-08
ZA201804458B (en) 2019-09-25
BR112018014671A2 (pt) 2018-12-11
SG11201805784PA (en) 2018-08-30
EA201891656A1 (ru) 2018-12-28
CN108602871A (zh) 2018-09-28
WO2017127514A1 (en) 2017-07-27
US20170204154A1 (en) 2017-07-20
CL2018001951A1 (es) 2018-12-28
JP6983787B2 (ja) 2021-12-17
US20190202881A1 (en) 2019-07-04
JP2019507589A (ja) 2019-03-22
US20210070828A1 (en) 2021-03-11
US10294287B2 (en) 2019-05-21
US11535657B2 (en) 2022-12-27
US20190153058A1 (en) 2019-05-23
US10774126B2 (en) 2020-09-15
KR20180100237A (ko) 2018-09-07
EP3405482A1 (en) 2018-11-28
AU2017210187A1 (en) 2018-07-19
US10875901B2 (en) 2020-12-29
US20200115429A1 (en) 2020-04-16
CA3010621A1 (en) 2017-07-27
EP3405482A4 (en) 2019-06-26
JP2022058337A (ja) 2022-04-12
US20180037624A1 (en) 2018-02-08
MX2018008840A (es) 2018-11-09
AU2021257949A1 (en) 2021-11-25
AU2017210187B2 (en) 2021-10-07
ECSP18062614A (es) 2018-10-31

Similar Documents

Publication Publication Date Title
CO2018008558A2 (es) Moléculas que activan selectivamente las células t reguladoras para el tratamiento de enfermedades autoinmunes
MX2017000821A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
UY36021A (es) Proteìnas fc multimèricas
NI201800121A (es) Proteínas de fusión gdf15 y usos de estas
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
JO3658B1 (ar) بروتينات اندماج
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
UA118286C2 (uk) Білок агоніст рецептора trail
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
EA201790371A1 (ru) Модифицированные варианты il-2, которые селективно активируют регуляторные т-клетки, для лечения аутоиммунных заболеваний
MX390878B (es) Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
EA201691686A1 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
MX373805B (es) Agonistas de receptor fgf21 y usos del mismo.
CR20190480A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
CL2019000846A1 (es) Proteína terapéutica.
EP3594242A4 (en) FUSION PROTEIN ACTIVATING NK CELLS, NK CELLS AND PHARMACEUTICAL COMPOSITION CONSISTING OF
BR112019011461A2 (pt) terapia celular à base de nk melhorada
EP3313526A4 (en) B1SP FUSION PROTEIN THERAPEUTICS, METHOD AND USES